Husband, dad, cardiologist, cardiovascular researcher and Irishman. Tweets ≠ advice
Boston, MA
Joined March 2020
- Tweets566
- Following92
- Followers1.5K
- Likes4.8K
Tomas G. Neilan, MD, MPH retweeted
Cancer therapies can carry CV risks, but current safety tools fall short. The Cardiac Safety Research Consortium led a multi-stakeholder think tank to improve CV safety reporting in oncology trials. Read the findings + next steps in #JACCCardioOnc: jacc.org/doi/10.1016/j.jacca…
Tomas G. Neilan, MD, MPH retweeted
⭐️NEW PAPER OUT in @Nature⭐️
🫀What is the relationship between the immune responses in the heart, blood, and tumor in patients with inflammation in the heart resulting from cancer immunotherapy (irMyocarditis)?
This 🧵 breaks down the key findings
1/n
nature.com/articles/s41586-0…
Tomas G. Neilan, MD, MPH retweeted
We
👉 Identify novel biomarkers of irMyocarditis onset and severity.
👉 Implicate non-immune cells in pathogenesis.
👉 Suggest that Tcell responses in the heart are distinct from those in tumors.
We hope that our findings will help to develop strategies to mitigate irMyocarditis
Tomas G. Neilan, MD, MPH retweeted
🌟 Antigens in irMyocarditis
🔍 None of the 52 most expanded TCRs from across 8 irMyocarditis patients responded to the heart proteins α-myosin, troponin I, or T.
👉 This suggests that the most expanded intracardiac T cell clones recognize novel autoantigen(s).
7/n
Tomas G. Neilan, MD, MPH retweeted
🌟 TCR clonality heart-tumor
🔍 Expanded heart clones ≠ expanded tumor clones
👉 Distinct T-cell clones suggest that T-cell responses in these patients may be directed against distinct antigens, providing hope to disentangle irMyocarditis from anti-tumor responses.
5/n
In @Nature, a collaboration with @kreynoldsMD, @villanilab, @sm_blum, @DZlotoff from @MGHCancerCenter, @MGHMedicine and others. Immune response in checkpoint myocarditis. Sincere thanks to the patients and families. @mghcvrc @ICOSociety. @MGHHeartHealth
nature.com/articles/s41586-0…
Very proud of amazing @ginny314gs from @mghmedres. Co-led with @kreynoldsMD from @MGHCancerCenter. Large language models with an excellent sensitivity and specificity for several key ICI associated adverse events and in 9 secs. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Congrats @HanZhuMD. That is so well deserved and in an area of limited research.
Proud to announce that we are now an R01 funded lab! We will be using single cell multi-omics in human samples & mouse models to test novel therapeutic pathways in cardiac sarcoidosis. #cardioimmunology @nih_nhlbi @NIH @StanfordCVI @StanfordDeptMed @Joseph_C_Wu @SeanM_Wu @EldrinL
Tomas G. Neilan, MD, MPH retweeted
Fantastic to be a part of this collaborative effort which made the cover of Nature Reviews Cardiology!! Thanks to Zoltan Varga and team members @kallikourdis @TomasNeilan @WCFWMeijers @.TamasGergely nature.com/nrcardio/
Tomas G. Neilan, MD, MPH retweeted
Very proud of rising ⭐️Ginny Sun for her poster on #LLM to detect #irae of #ICI therapy based free text notes on #ASCO24 🏁9 sec’s per chart to find 90+ % complex toxicities is nothing short of phenomenal. By far outperformed ICD codes. Amazing team @kreynoldsMD @TomasNeilan
Tomas G. Neilan, MD, MPH retweeted
Exclusion of pts w/ prior #cancer diagnosis from CV trials poses a significant (and peristent) barrier! 🌎🌍🌏There is an increase in pts with co-existing cancer &CVD ➡️growing gap in knowledge regarding these promising CV drugs! @ICOSociety #CardioOnc
Congrats @JJheart_doc. Like so many on here, I have been very lucky to call you a colleague, mentor and friend. So extremely well deserved.
I’m proud to announce Dr. Jim Januzzi’s promotion to Chief Scientific Officer @BaimInstitute (formerly Harvard Clinical Research Institute or HCRI). BaimInstitute.org
Dr. Januzzi is a brilliant clinical researcher and an academic superstar. His groundbreaking work in the field of biomarkers and congestive heart failure have earned him the respect and admiration of cardiologists around the world.
His patients are fortunate to have him guiding their care @MGHMedicine which he will continue to do in his dual role.
We value his tireless efforts and his dedication to Baim and its academic mission.
We look forward to his contributions in shaping the academic and strategic vision of Baim in the years to come.
Join me in congratulating Dr. Januzzi on his well deserved recognition and promotion!
Congratulations @salimhayek. That is a well deserved and amazing accomplishment.
Humbled and honored to accept the responsibility of interim Chair of the Department of Medicine @utmbhealth. I commit to provide unwavering support to our department and
division leaders as we drive transformational changes in academic medicine at UTMB.
Congrats @SarjuGanatraMD. Another amazing accomplishment
🌍 Humbled to serve as the inaugural Medical Director of Sustainability @LaheyHospital
It's time to foster a health system that heals both 👨👩👦👦 & 🌍
This role represents a pivotal paradigm shift, guided by the vision of our President @smoffattbruce1
⚖️ Planetary Health
✔️ Environmental determinants of (our) health
🏥💪System resilience
🌳 ♻️ Sustainable (social, environmental, economical...) future of the community
🏥 #SustainableHealthcare #HealthForAll #Sustainability
Tomas G. Neilan, MD, MPH retweeted
Interested in studying how the brain controls our cardiovascular health? Come and join our growing lab at MGH and HMS as a PostDoc. Expect full support, scientific freedom, and a very friendly environment. Check here for details xitter.cf/jobRxiv/status/1770102… Please RT!
Postdoctoral Fellow in Experimental Neurocardiology at MGH/HMS @mghcvrc
Interested in studying how the brain controls our cardiovascular health? Come and join our growing lab at MGH and HMS as a PostDoc.
jobrxiv.org/job/massachusett…
#cardiovascular_diseas...
jobrxiv.org/job/massachusett…
Tomas G. Neilan, MD, MPH retweeted
🫀Don't miss this original research from a great team in @JACCJournals! 📰tinyurl.com/bu4kxxnf
@AminNassarMD @DrChoueiri @DrSarcoma @TomasNeilan @ADesaiMD @hannadallapria @RyanDenu #JACCCardioOnc
Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was observed in a subset of patients w/ nonangiosarcoma, albeit w/ higher toxicity. bit.ly/3OvJiYD
#JACCCardioOnc #CardioOnc #Immunotherapy @AminNassarMD
Tomas G. Neilan, MD, MPH retweeted
This @AHAScience statement is the result of an effort by a multidisciplinary of adult and pediatric experts from around the nation including #CardioOnc and #Hematology to finally bring you evidence-based guidance on the cardiovascular management of patients undergoing BMT. – at Ann Arbor, MI
Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship #AHAJournals
ahajrnls.org/48OpeaQ
Tomas G. Neilan, MD, MPH retweeted
🚨 irAE aficionados! Still time to register for the inaugural irAE consortium (3/7) and the CME course on irAE (3/7-3/8) - both hybrid!
Also a few seats left for an inperson benefit dinner to launch a patient advocacy group on Thur March 7th #dineandgive
ghlf.org/irae-consortium/
Tomas G. Neilan, MD, MPH retweeted
Join us for an engaging session, moderated by @BlaesAnneMD & @TomasNeilan, at this year's #MSKCardioOncCME, where we'll explore the latest advancements in #LungCancer care and their impact on #Cardiovascular health.
Register by March 1 for early rates 🔜 bit.ly/MSKCardioOnc2024
ALT Lung Cancer: Advances in Treatment and Their Impact on Cardiovascular Health
Tomas G. Neilan, MD, MPH retweeted
Learn about variability in LVEF assessments and its impact on cardiotoxicity detection.
Suero-Abreu et al (journalofnuclearcardiology.o…)
Editorial (journalofnuclearcardiology.o…)
#CTRCD #LVEF #ERNA @alfonsowallermd @GiselleSA_MDPhD #cardioonc @MyASNC #cvnuc
